1d
Clinical Trials Arena on MSNBioCity and MSD to evaluate cancer treatment combination in Phase I/II trialBioCity Biopharmaceuticals and MSD have signed a clinical trial partnership agreement to assess BC3195 in conjunction with ...
On January 6, 2025, the US Food and Drug Administration (FDA) and the US Department of Health and Human Services (HHS) Office for Human ...
At the ADC Asia Congress 2025 held today (3/12) in Singapore, OBI Pharma (4174.TWO) was honored with the "Most Promising ADC Clinical Candidate in Taiwan" award. This recognition follows OBI Pharma’s ...
Posters presented at the Association of Cancer Care Centers opening session covered initiatives to boost clinical trial ...
NetraMark's first presentation, " Novel Machine Learning Approach Outperforms Traditional Approaches in Major Depressive Disorder Clinical Trials", demonstrated how NetraAI Sub-Insight Learning ...
The stress axis that has been most extensively studied in relation to stress is unquestionably the hypothalamic pituitary ...
discussed FDA's recent guidance on protocol deviations and its impact on clinical trial management. She highlighted the importance of quality by design (QbD) and critical to quality (CTQ) factors in ...
developing key patient-centred ethical research platforms for sustained trials linked to health systems; and adopting innovations in trial design that can accelerate trials further, such as through ...
Medical students who fail to present their poster on Symposium Day without prior notification will not be considered for poster presentation at future symposiums. In addition to presenting in person, ...
operational results and the design clinical trials, which are based upon NetraMark's current internal expectations, estimates, projections, assumptions and beliefs, and views of future events.
TORONTO--(BUSINESS WIRE)--Satellos Bioscience Inc. (TSX: MSCL, OTCQB: MSCLF) (“Satellos” or the “Company”), a public biotech company developing new small molecule therapeutic approaches to ...
Based on precedents from other Phase 3 trials in Crohn’s disease, we believe that VTX958 has the potential to show greater placebo-adjusted clinical remission rates with longer duration of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results